Literature DB >> 16983662

Morphine upregulates functional expression of neurokinin-1 receptor in neurons.

Qi Wan1, Steven D Douglas, Xu Wang, Dennis L Kolson, Lauren A O'Donnell, Wen-Zhe Ho.   

Abstract

Neuronkinin-1 receptor (NK-1R), the neuropeptide substance P (SP) preferring receptor, is highly expressed in areas of the central nervous system (CNS) that are especially implicated in depression, anxiety, and stress. Repeated exposure to opioids may sensitize neuronal systems involved in stress response. We examined the effects of morphine, the principal metabolite of heroin, on the functional expression of NK-1R in the cortical neurons. NK-1R and mu-opioid receptor (MOR) are co-expressed in the cortical neurons. Morphine enhanced NK-1R expression in the cortical neurons at both the mRNA and protein levels. The upregulated NK-1R by morphine had functional activity, because morphine-treated cortical neurons had greater SP-induced Ca(2+) mobilization than untreated neurons. Blocking opioid receptors on the cortical neurons by naltrexone or CTAP (a mu-opioid receptor antagonist) abolished the morphine action. Investigation of the mechanism(s) responsible for the morphine action showed that morphine activated NK-1R promoter and induced the phosphorylation of p38 MAPK protein in the cortical neurons. These in vitro data provide a plausible cellular mechanism for opioid-mediated neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16983662     DOI: 10.1002/jnr.21053

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.

Authors:  Jie Xiao; Si Zeng; Xiangrui Wang; Hasan Babazada; Zhanchun Li; Renyu Liu; Weifeng Yu
Journal:  Transl Perioper Pain Med       Date:  2016

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

4.  PTEN gene silencing prevents HIV-1 gp120(IIIB)-induced degeneration of striatal neurons.

Authors:  Shiping Zou; Nazira El-Hage; Elizabeth M Podhaizer; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurovirol       Date:  2011-01-14       Impact factor: 2.643

5.  Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain.

Authors:  Elizabeth M Podhaizer; Shiping Zou; Sylvia Fitting; Kimberly L Samano; Nazira El-Hage; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-19       Impact factor: 4.147

6.  Morphine suppresses intracellular interferon-alpha expression in neuronal cells.

Authors:  Qi Wan; Xu Wang; Yan-Jian Wang; Li Song; Shi-Hong Wang; Wen-Zhe Ho
Journal:  J Neuroimmunol       Date:  2008-06-17       Impact factor: 3.478

7.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Authors:  T M Largent-Milnes; S W Brookshire; D P Skinner; K E Hanlon; D Giuvelis; T Yamamoto; P Davis; C R Campos; P Nair; S Deekonda; E J Bilsky; F Porreca; V J Hruby; T W Vanderah
Journal:  J Pharmacol Exp Ther       Date:  2013-07-16       Impact factor: 4.030

8.  The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.

Authors:  Frances E Lennon; Tamara Mirzapoiazova; Bolot Mambetsariev; Valeriy A Poroyko; Ravi Salgia; Jonathan Moss; Patrick A Singleton
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

9.  In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.

Authors:  Joanna Matalińska; Piotr F J Lipiński; Piotr Kosson; Katarzyna Kosińska; Aleksandra Misicka
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.